Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Axsome Therapeutics, Inc is a biotechnology business based in the US. Axsome Therapeutics shares (AXSM) are listed on the NASDAQ and all prices are listed in US Dollars. Axsome Therapeutics employs 43 staff and has a market cap (total outstanding shares value) of USD$2.7 billion.
Since the stock market crash in March caused by coronavirus, Axsome Therapeutics's share price has had significant negative movement.
Its last market close was USD$74.29, which is 18.48% down on its pre-crash value of USD$91.13 and 109.62% up on the lowest point reached during the March crash when the shares fell as low as USD$35.44.
If you had bought USD$1,000 worth of Axsome Therapeutics shares at the start of February 2020, those shares would have been worth USD$680.64 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$791.19.
|Latest market close||USD$74.29|
|52-week range||USD$20.48 - USD$109.94|
|50-day moving average||USD$74.8616|
|200-day moving average||USD$77.3999|
|Wall St. target price||USD$146.8|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.374|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-23)||4.75%|
|1 month (2020-10-30)||12.03%|
|3 months (2020-08-28)||-2.52%|
|6 months (2020-05-29)||-3.49%|
|1 year (2019-11-29)||88.70%|
|2 years (2018-11-30)||2,178.83%|
|3 years (2017-11-30)||1,214.87%|
|5 years (2015-11-30)||741.34%|
|Gross profit TTM||USD$0|
|Return on assets TTM||-47.56%|
|Return on equity TTM||-106.15%|
|Market capitalisation||USD$2.7 billion|
TTM: trailing 12 months
There are currently 3.8 million Axsome Therapeutics shares held short by investors – that's known as Axsome Therapeutics's "short interest". This figure is 4.1% up from 3.7 million last month.
There are a few different ways that this level of interest in shorting Axsome Therapeutics shares can be evaluated.
Axsome Therapeutics's "short interest ratio" (SIR) is the quantity of Axsome Therapeutics shares currently shorted divided by the average quantity of Axsome Therapeutics shares traded daily (recently around 532323.25905292). Axsome Therapeutics's SIR currently stands at 7.18. In other words for every 100,000 Axsome Therapeutics shares traded daily on the market, roughly 7180 shares are currently held short.
However Axsome Therapeutics's short interest can also be evaluated against the total number of Axsome Therapeutics shares, or, against the total number of tradable Axsome Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Axsome Therapeutics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Axsome Therapeutics shares in existence, roughly 100 shares are currently held short) or 0.1316% of the tradable shares (for every 100,000 tradable Axsome Therapeutics shares, roughly 132 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Axsome Therapeutics.
Find out more about how you can short Axsome Therapeutics stock.
We're not expecting Axsome Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Axsome Therapeutics's shares have ranged in value from as little as $20.48 up to $109.94. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Axsome Therapeutics's is 2.8075. This would suggest that Axsome Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the phase III clinical trial for the treatment resistant depression and depressive disorders; and phase II/III clinical trials in agitation associated with Alzheimer's disease, as well as completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07, which is in phase III clinical trial for the treatment of migraine; AXS-09 that has completed phase II clinical trial for the treatment of various CNS disorders; AXS-12, which has completed phase II clinical trial for the treatment of in narcolepsy; and AXS-14, an investigational medicine that is in phase III for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was founded in 2012 and is based in New York, New York.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.